Nontherapeutic Risk Factors of Different Grouped Stage IIIC Breast Cancer Patients’ Mortality: A Study of the US Surveillance, Epidemiology, and End Results Database

Table 1

Clinicopathological features of patients with stage IIIC breast cancers.

Category	n = 1673
Age at diagnosis (year)
≤40 years old	148 (8.85%)
>40 years old	1525 (91.15%)
Laterality
Left	832 (49.73%)
Right	841 (50.27%)
Primary site
Upper-inner	102 (6.10%)
Upper-outer	594 (35.51%)
Lower-inner	51 (3.05%)
Lower-outer	102 (6.10%)
Other types	824 (49.25%)
Histological type
Infiltrating duct carcinoma	1071 (64.02%)
Lobular carcinoma	354 (21.16%)
Infiltrating duct and lobularcarcinoma	177 (10.58%)
Other types	71 (4.24%)
Histological grade
Well-differentiated	149 (8.91%)
Moderately differentiated	748 (44.71%)
Poorly differentiated	772 (46.14%)
Undifferentiated	4 (0.24%)
Molecular typing
Luminal A	1138 (68.02%)
Luminal B	188 (11.24%)
HER-2 positive	131 (7.83%)
Triple negative	216 (12.91%)
ER status
Positive	1305 (78.00%)
Negative	368 (22.00%)
PR status
Positive	1088 (65.03%)
Negative	585 (34.97%)
HER-2 status
Positive	319 (19.07%)
Negative	1354 (80.93%)
T stage
T1	260 (15.54%)
T2	755 (45.13%)
T3	474 (28.33%)
T4	184 (11.00%)
N3 stage
N3a	1426 (85.24%)
N3b	166 (9.92%)
N3c	81 (4.84%)
LNP
<14	943 (56.37%)
≥14	730 (43.63%)
LNR
<0.8148	925 (55.29%)
≥0.8148	748 (44.71%)
Follow-up time (month), IQR	54 (38∼72)
5-year OS	51.72% (95% CI: 0.4838∼0.5495)
5-year DSS	60.74% (95% CI: 0.5735∼0.6395)

ER: estrogen receptor. HER-2: human epidermal growth factor receptor 2. LNP: positive lymph nodes. LNR: lymph node ratio. PR: progesterone receptor. IQR: interquartile range. DSS: disease-specific survival. OS: overall survival. CI: confidence interval.